Dr. Rattel is Executive Director at Amgen and he has been responsible for the nonclinical assessment of bispecific BiTE antibodies since 2008.
Formerly, he was Vice President of Nonclinical Development at Micromet and at GPC Biotech, and before that Director of Toxicology and Pharmacology at Fujisawa. He also consulted various European Biotech Companies as well Scientific Societies in nonclinical drug development.
Dr. Rattel has more than 30 years of drug development experience and is board-certified in pharmacology, toxicology and animal welfare and an European-Registered Toxicologist. He is member of a number of professional societies and has studied veterinary medicine at the LMU Munich, where he was granted his doctorate.